itm-radiopharma.comCrawled Oct 24, 2026
EndolucinBeta
These pages are currently being updated and will be available again soon.
iQS-TS is a multipurpose automated cassette-based theranostics synthesizer facilitating the routine preparation of radiolabeled biomolecules.
ITM develops radiopharmaceutical therapies for targeted cancer treatment.
ITM offers radioisotopes and radiopharmaceuticals, with availability varying by country.
The 2010 Nordic Guidelines outline diagnosis and treatment protocols for gastroenteropancreatic neuroendocrine tumors.
ITM and Lumara Bio Announce Dose-Response Analysis for ¹⁷⁷Lu-edotreotide (ITM-11) and Data Supporting Early-Stage Pipeline at EANM 2026
ITM shares press releases, media coverage, and updates on radiopharmaceutical research and cancer therapy breakthroughs.
ITM Radiopharmaceuticals offers career opportunities in science, technology, and innovation focused on precision cancer therapies.
The COMPETE trial compared 177Lu-edotreotide and everolimus for treating somatostatin receptor-positive neuroendocrine tumors.
Chief Executive Officer ITM Group. Dr. Andrew Cavey became Chief Executive Officer of ITM Isotope Technologies Munich AG in September 2024.
VP Product Management & Business Development ITG, Managing Director ITM Oncologics & ITM Solucin. Konstantin joined the itm Group as Head of Product Management in 2012
Managing Director ITG, Head of Production and R & D. Mark joined the ITM Group as Head of Production and R&D in 2008. Under Mark
Head of Sales. Sebastian was appointed Head of Sales in February 2014 and is responsible for driving itm Group growth by further expanding the global sales partner network.
ITM’s Code of Conduct guides employees, management, and supervisory board members in ethical interactions with patients and partners.
ITM AG was founded in 2004 to develop and produce next generation radionuclides for Targeted Radionuclide Therapy in Precision Oncology.
ITM partners with healthcare and biotech organizations to advance radiopharmaceutical innovation, education, and patient advocacy.
ITM provides information on radiopharmaceutical innovation, partnerships, and patient support.
* Please note, that we do not offer personalized medical advice or patient-specific treatment advice. Only your doctor or other health care professional can determine if a product described in this website is appropriate for you.
At ITM, precision drives everything - from isotope manufacturing to cancer treatment—improving outcomes and delivering what patients and physicians expect.
https://www.itm-radiopharma.com/service/privacy-policy/
ITM’s social media guidelines restrict discussions of specific products, treatments, or medical advice due to regulatory requirements.
The copyright in this website and the material on this website (including without limitation the text, computer code, artwork, photographs, images, music, audio material, video material and audio-visual material on this website) is owned by ITM Isotope Technologies Munich SE and its licensors.
ITM’s General Terms and Conditions apply to its German affiliates and govern sales agreements for goods and services.
ITM Isotope Technologies Munich SE Lichtenbergstrasse 1 85748 Garching / Munich, Germany Email: info@itm-radiopharma.com Phone: +49 89 329 8986 6000 Fax: +49 89 329 8986 6061
